Release Date: November 07, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Can you provide more color on the expected sequential step-up in surgical glaucoma utilization in Q4, given the headwinds around the LCD? A: Alison Bauerlein, CFO, explained that historically, Q4 utilization is higher than Q3 due to seasonality. Improvements have been seen early in the quarter, and a targeted plan is being executed. Dry eye sales are ahead of expectations, which offsets some glaucoma shortfalls. Matt Link, CCO, added that the finalized LCD provides market certainty, allowing for deliberate re-engagement with accounts and providers.
Q: Could you explain the calculation for device-intensive status and why OMNI did not qualify in the final rule? A: Matt Link, CCO, stated that the specific claims data used for the calculation is not yet available. The process involves analyzing 2023 claims data, and the final determination showed OMNI fell below the 30% threshold. The company is committed to ensuring accurate billing data and will review the claims data once available to understand the requirements for achieving device-intensive status.
Q: How have the restrictions on multiple MIGS procedures impacted your business, and what are your expectations for 2025? A: Alison Bauerlein, CFO, noted that while the company doesn't have specific data on the impact of combination MIGS restrictions, they are proactively discussing plans with customers. The comprehensive nature of the OMNI procedure provides a unique value proposition. No specific 2025 guidance was provided, but the company is focused on leveraging OMNI's strengths.
Q: Can you discuss the progress and expectations for achieving cash flow break-even and free cash flow positivity? A: Alison Bauerlein, CFO, highlighted significant reductions in cash burn and improvements in working capital. While specific guidance on cash flow break-even is not provided, the company is focused on expense management and strategic investments, particularly in tier care market access and pipeline activities. The company feels sufficiently capitalized to support these initiatives.
Q: What is the current status and future outlook for the standalone glaucoma market? A: Matt Link, CCO, explained that the standalone market is in early development, requiring a paradigm shift in patient care. The company is focused on aligning with physicians to impact patient outcomes positively. Paul Badawi, CEO, added that real-world data from the Iris Registry supports OMNI's efficacy, with a publication expected in 2025 to further develop the standalone market.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.